EnteroMedics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2011. For the quarter, the company reported loss from operations of $7.885 million and net loss of $8.056 million or $0.22 per basic and diluted share compared to loss from operations of $3.620 million and net loss of $3.955 million or $0.34 per basic and diluted share for the same period a year ago. For the year, the company reported loss from operations of $25.257 million and net loss of $25.997 million or $0.86 per basic and diluted share compared to loss from operations of $16.177 million and net loss of $17.347 million or $2.06 per basic and diluted share for the same period a year ago. The Company also announced that it has received approvals for the final Maestro System components from the Therapeutic Goods Administration (TGA) for listing on the Australian Register of Therapeutic Goods (ARTG). The Company previously announced approvals for a majority of the components of the Maestro System. The listing of these remaining components by the TGA on the ARTG completes the approval for listing of all components of the Maestro System in Australia. Full approval by the TGA for listing on the ARTG enables EnteroMedics to aggressively move forward with commercialization of the Maestro System in Australia, a country where more than 60% of the population is overweight or obese.